13.62
전일 마감가:
$13.49
열려 있는:
$13.46
하루 거래량:
62,228
Relative Volume:
0.07
시가총액:
$558.46M
수익:
-
순이익/손실:
$-168.05M
주가수익비율:
-2.654
EPS:
-5.13
순현금흐름:
$-146.15M
1주 성능:
-0.51%
1개월 성능:
-6.73%
6개월 성능:
-20.62%
1년 성능:
-70.74%
Keros Therapeutics Inc Stock (KROS) Company Profile
명칭
Keros Therapeutics Inc
전화
617-314-6297
주소
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
KROS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
KROS
Keros Therapeutics Inc
|
13.62 | 558.46M | 0 | -168.05M | -146.15M | -5.13 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
441.01 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
512.43 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
310.24 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
536.59 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.81 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-06-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
2025-01-21 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2025-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
2024-12-16 | 다운그레이드 | Guggenheim | Buy → Neutral |
2024-12-16 | 재확인 | Oppenheimer | Outperform |
2024-12-13 | 재확인 | H.C. Wainwright | Buy |
2024-12-12 | 다운그레이드 | BTIG Research | Buy → Neutral |
2024-12-12 | 다운그레이드 | TD Cowen | Buy → Hold |
2024-12-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2024-11-05 | 개시 | Jefferies | Buy |
2024-10-24 | 개시 | Cantor Fitzgerald | Overweight |
2024-10-16 | 개시 | Scotiabank | Sector Outperform |
2024-09-23 | 개시 | Guggenheim | Buy |
2024-06-25 | 개시 | Oppenheimer | Outperform |
2024-02-21 | 개시 | William Blair | Outperform |
2023-12-08 | 개시 | Wells Fargo | Overweight |
2023-07-31 | 개시 | Wedbush | Outperform |
2023-07-26 | 개시 | BofA Securities | Buy |
2023-02-14 | 개시 | Cowen | Outperform |
2022-10-18 | 개시 | Truist | Buy |
2022-07-26 | 개시 | BTIG Research | Buy |
2020-12-08 | 재확인 | H.C. Wainwright | Buy |
2020-05-04 | 개시 | H.C. Wainwright | Buy |
2020-05-04 | 개시 | Jefferies | Buy |
2020-05-04 | 개시 | Piper Sandler | Overweight |
2020-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
(KROS) Trading Report - news.stocktradersdaily.com
Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56 - MarketBeat
Bank of America Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat
Two Sigma Investments LP Buys 23,342 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Shares Gap DownTime to Sell? - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Bank of America - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst - Benzinga
Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says - MarketScreener
BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32 - marketscreener.com
KROS: Keros Therapeutics Receives Downgrade from B of A Securities | KROS Stock News - GuruFocus
Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst - GuruFocus
Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst | KROS Stock News - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
ADAR1 Demands Bigger Payouts From Keros Therapeutics - Finimize
Keros Therapeutics to return $375 million to shareholders By Investing.com - Investing.com South Africa
ADAR1 Capital Management Calls For Keros Therapeutics To Return $475 Mln To Stockholders By Q3 - marketscreener.com
Keros Directors Face Massive Shareholder Revolt: ADAR1 Pushes for $475M Dividend and Board Overhaul - Stock Titan
Keros Therapeutics (KROS) to Return $375M Capital to Shareholders | KROS Stock News - GuruFocus
Keros Therapeutics Concludes Strategic Alternatives Review - TipRanks
Keros to Return $375 Million to Shareholders Following Strategic Review - marketscreener.com
Keros Announces Return of $375 Million in Excess Capital to Stockholders - The Manila Times
Keros Therapeutics to return $375 million to shareholders - Investing.com
Keros Therapeutics Announces $375 Million Capital Return Plan Following Strategic Review - Nasdaq
Keros Concludes Strategic Review: Massive $375M Shareholder Return While Advancing DMD Drug Development - Stock Titan
Nuveen Asset Management LLC Sells 181,863 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Wellington Management Group LLP - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Position Boosted by Two Sigma Investments LP - Defense World
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan
Two Sigma Advisers LP Has $328,000 Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Nuveen Asset Management LLC Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics (NASDAQ:KROS) Receives Neutral Rating from Wedbush - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.9%Should You Sell? - MarketBeat
ProShare Advisors LLC Purchases 2,764 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Bank of America Corp DE - Defense World
D. E. Shaw & Co. Inc. Cuts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,386 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Deutsche Bank AG Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | - GuruFocus
KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | KROS Stock News - GuruFocus
TFG Asset Management GP Ltd Acquires New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics halts PAH drug development, cuts workforce By Investing.com - Investing.com South Africa
Keros Therapeutics Inc (KROS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Keros Therapeutics Inc 주식 (KROS) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Seehra Jasbir | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
0.30 |
49,367 |
14,810 |
302,223 |
GORDON CARL L | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
ORBIMED ADVISORS LLC | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
자본화:
|
볼륨(24시간):